A look back at the week's news.
Teenaged girls at average risk don’t need Papanicolaou tests, but some special populations do.
Best practices on discussing birth control for adolescents.
If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).
Check out these latest resources from the American Urogynecologic Society.
Changes for ICD-10 documentation codes that go into effect in October 2022.
Tips to avoid wasting time and optimize meetings you do need.
A legacy of excellence: Reflecting on the final print edition of Contemporary OB/GYN
April 25th 2025Marking the end of an era and the beginning of a new chapter, the final print edition of Contemporary OB/GYN celebrates over 50 years of evidence-based guidance and unwavering support for clinicians.
Read More